Month: August 2025

Roseville, Minnesota, Aug. 01, 2025 (GLOBE NEWSWIRE) — SecureTech Innovations, Inc. (OTCQB: SCTH), a pioneering technology company advancing artificial intelligence, industrial 3D printing and manufacturing technologies, cybersecurity, and digital infrastructure solutions, is pleased to announce that its common stock has been approved for trading on the OTCQB® Venture Market, effective immediately. The OTCQB Venture Market, operated by OTC Markets Group Inc., is recognized by the U.S. Securities and Exchange Commission (SEC) as an established public market, the first tier within the OTC framework to receive such recognition. It serves early-stage and developing U.S. and international companies that meet strict financial standards, maintain current reporting with the SEC or a U.S. banking regulator, and complete annual verification...

Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC plus ALLO-647) Lymphodepletion Arm Unplanned Review of Safety and Biomarker Data with Standard FC and Cema-cel Indicates Encouraging MRD Conversion Rate and Safety Profile ALPHA3 Study Now Proceeds as a Two-Arm Randomized Study Comparing Cema-cel After Standard FC Lymphodepletion to Observation; Scheduled Futility Analysis Remains 1H 2026, as Planned Conference Call and Webcast Scheduled for Today at 8:00 AM PT/11:00 AM ETSOUTH SAN FRANCISCO, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares (ADSs) representing 76,666,668 ordinary shares at an offering price of $1.95 per ADS, for total gross proceeds of approximately $65 million. All of the ADSs to be sold in the offering will be offered by I-Mab. The offering is expected to close on August 5, 2025, subject to customary closing conditions. The offering included participation from new and existing investors including Everest Medicines, Janus Henderson Investors, Adage Capital Partners LP and Exome Asset Management. Leerink Partners is acting...

NEW ALBANY, Ohio, Aug. 01, 2025 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF) will host its quarterly earnings conference call for all interested parties on Wednesday, August 27, 2025, at 8:30 a.m. ET. A press release detailing the company’s second quarter results is expected to be issued shortly after 7:30 a.m. ET.   In addition, a presentation of the second quarter results will be available on the company’s website at approximately 7:30 a.m. ET.Conference Call: To access the conference call by phone, participants will need to register to obtain a dial-in phone number and an access code. Register for the call using this link.   Webcast: To listen to a live webcast of the call, please visit corporate.abercrombie.com/investors/news-and-events/events/ and click the link to the webcast.   Replay: A replay...

CUPERTINO, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its second quarter 2025 earnings report: Date: Thursday, August 7, 2025 Time: 11 am Pacific Time (PT) Live Participant Dial In (Toll Free): +1-888-506-0062 entry code 655740  Live Participant Dial In (International): +1-973-528-0011 entry code 655740 Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/52764 Attendees may submit questions during the Q&A (Questions & Answers) portion of the conference call. The webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls, along with the company presentation, recent announcements, and video recordings. The voice recording will be available through August 14, 2025, by...

CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 55,450 restricted stock units (“RSUs”) to four newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). About Solid BiosciencesSolid...

ROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that the Company’s management will participate in the Evercore China Biotech Summit being held on August 19 – 21, 2025 in Shanghai, China. Management will be participating in a fireside chat moderated by the Evercore ISI Research team and one-on-one investor meetings at the conference. Investors interested in scheduling a meeting with the Ascentage Pharma management team should contact their Evercore representative. About Ascentage Pharma Group International Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or...

Hauppauge, NY, Aug. 01, 2025 (GLOBE NEWSWIRE) — – Cemtrex Inc. (Nasdaq: CETX), a technology company focused on intelligent security and industrial services, today issued a shareholder update from Chairman and CEO Saagar Govil outlining the Company’s progress across its core divisions and strategic roadmap for long-term growth: To our shareholders, Cemtrex today is stronger, sharper, and more focused than at any point in the last several years. We’ve been building deliberately investing in the right products, winning critical contracts, and executing a strategy that positions us to lead where the world is heading. Vicon: Momentum, Execution, and the Launch of NEXT Vicon, our intelligent security division, is performing. Since 2021, we’ve grown revenue from $21 million to a projected $36 million-plus for fiscal year 2025. Gross...